Program

Tuesday 25 August

1100 – 1230 Study Coordinator Meeting 1

Co-Chairs: Ms Laura Carolan & Ms Sally Dean

The Study Coordinator workshop provides an interesting education program covering a wide range of topics presented by highly regarded experts in the field.These workshops present a fantastic opportunity to interact with leaders in their field, and Study Coordinators will return with a broader insight and appreciation into the world of research in oncology.

  • How to Prepare for an Audit – Ms Anne Woollett
  • Clinical Trials Design & Statistics – Ms Rebecca Asher
  • Conducting Clinical Trials in New Zealand – Dr Sarah Benge
1100 – 1230 Trainee Workshop 1

Gastric Cancer Mini Preceptorship – ‘Presentations by Trainees of the seminal paper summaries’

Co-Chairs: Dr Mark McGregor & Dr Sharon Pattison

This exciting initiative will aim to cover surgical, radiation, medical oncology and translational science as aspects of study of gastric cancer. Our Invited Faculty will nominate the seminal publications in their field for nominated trainees to review; we will then invite other trainees to present illustrative gastric cancer cases highlighting where the learned evidence could be used to assist decision making.The Invited Faculty will have access to the trainee summaries and case presentations prior to the meeting and will provide comment and instruction on the day.

Preceptors:

  • Medical Oncology: Dr Sharon Pattison
  • Surgery: Associate Professor Cuong Duong
  • Radiation Oncology: Professor Trevor Leong
  • Translational Science: Professor Alex Boussioutas
1230 – 1300 Lunch
1300 – 1430 Study Coordinator Meeting 2

C0-Chairs: Ms Roslynn Murphy & Ms Evonne Tim

Clinical research is part of an active global oncology community. Study Coordinators and Research Nurses are vital to the constant development of cancer biology and treatment, and it is essential that they develop knowledge and skills in research development and conduct. The Study Coordinator workshop covers a wide range of topics presented by experts in the field. Attendees will gain a broader insight into the world of oncology research.

  • Project Management, good research practices, ISF / source management tools to overcome recruitment and screening challenges – Ms Anne Woollett
  • Part 2 “The Evolving Worls of Clinical Trial Coordination” – Teletrials Operations – Ms Narelle McPhee
  • Early versus Late Phase Trials – Dr James Lynam
 

 

1300 – 1600 Trainee Workshop 2

Co-Chairs: Dr Mark McGregor & Dr Sharon Pattison

Gastric Cancer Mini Preceptorship continued – Case Presentations

1500 – 1700 WEHI and Peter MacCallum Cancer Centre  Tour

Details to follow

Wednesday 26 August

0700 – 1800 Registration Open  
0745 – 0845 Keynote Breakfast Session

Co Chairs: TBA

Theme: Rectal Cancer

Speaker: Professor Corrie Marijnen

0900 – 1030 Opening Plenary

Co-Chairs: TBA

Theme: Colorectal Molecular Subtypes

  • “Location, location, location. Relationship between tumour location, and colorectal cancer CMS and implications for practice” – Associate Professor Jonathan Loree
  • “Circulating tumour DNA – Where are we now?” – Dr Naureen Starling
  • Topic TBC – Dr Susan Woods
  • “Colorectal CMS – are we ready for prime time?” – Dr Jennifer Mooi
1030 – 1100 Morning Tea
1100 – 1300

 

AGITG Lower GI Cancer Trials

Co-Chairs: TBC

SPAR: A randomised, placebo controlled phase II trial of Simvastatin in addition to standard chemotherapy and radiation in preoperative treatment for rectal cancer

ASCOLT: Aspirin for Dukes C and High-Risk Dukes B Colorectal Cancers. An international, Multi-centre, Double-Blind, Randomised Placebo Controlled Phase III trial – PRESENTED WITH ASCOLT Translational

OXTOX: Can Oxaliplatin dose reduction and neurotoxicity be reduced with ibudilast in people with metastatic colorectal cancer – a phase II randomised study

SPAR, ASCOLT & OXTOX: Where do they fit in the International Context – Professor Jonathan Loree

RoLaCaRT-1: Robotic versus Laparoscopic Colon – a Randomized Trial. An international randomised phase II trial comparing robotic-assistEd right hemicolectomy versus laparoscopic-assisted hemicolectomy for resection of adenocarcinoma of the caecum, ascending or proximal transverse colon

AGITG ENDORSED STUDY:

RENO: Prospective Study of ‘Watch & Wait’ Strategy in Patients with Rectal Cancer who have developed a Clinical Complete Response with concurrent chemo-radiotherapy: RENO (Rectal Cancer No Operation)

RoLaCaRT-1 & RENO: Where do they fit in the International Context? – Professor Frank Frizelle

Recipient: 2018 Merck-AGITG Kristian Anderson Award – Dr Rosemary Habib

1300 – 1400 Lunch
1400 –1600 AGITG Colorectal Cancer Trials

Co-Chairs: TBA

MODULATE: Modulation of the tumour microenvironment using either vascular disrupting agents or STAT3 inhibition in order to synergise with PD1 inhibition in microsatillite stable, refactory colorectal cancer

MONARCC: A randomised phase 2 study of panitumumab monotherapy and panitumumab plus 5 fluorouracil as first line therapy for RAS and BRAF wild type metastatic colorectal cancer

POLEM: Avelumab plus fluoropyrimidine-based chemotherapy as adjuvant treatment for stage III dMMR or POLE exonuclease domain mutant colon cancer: A phase III randomised study

MODULATE, MONARCC & POLEM: Where do they fit in the International Context – Dr Naureen Starling

DYNAMIC-Rectal: Circulating Tumour DNA Analysis Informing Adjuvant Chemotherapy in Locally Advanced Rectal Cancer: A Multicentre Randomised Study, PRESENTED WITH

DYNAMIC III: Circulating tumour DNA Analysis Informing Adjuvant Chemotherapy in Stage III Colon Cancer: A Multicentre Randomised Study

DYNAMIC-Rectal & DYNAMIC-III; Where do they fit in the International Context – Dr Parry Guildford

FORECAST-1: Feasibility of Organoid Response assessment to define Effective Treatments for patients with Colorectal cancer After failure of Standard Therapy

FORECAST-1: Where does it fit in the International Context – Dr Jérôme Galon

Recipient: 2018 Merck Clinical Research Fellowship – Dr David Lau (TBC)

1400 – 1600 Radiation Oncology Workshop

Co-Chairs: Dr Meredith Johnson & Dr Andrew Oar

Theme: Gastric Cancer

Speakers: Professor Corrie Marijnen & Professor Trevor Leong

Topics: TBC

1600 – 1630 Afternoon Tea
1630 – 1800 Best of Posters / Fast Forward

The AGITG Annual Scientific Meeting accepts abstracts for posters for selection by the Executive Organising Committee.  Posters are displayed in the exhibition area.  Four posters are chosen for presentation in the Best of the Best Session. Each presenter has seven minutes to present with three minutes for questions. Four posters are also chosen for Fast Forward presentation. Each presenter has three minutes to present with two minutes for questions. The AGITG recognises excellence in the Posters and Fast Forward Sessions at each annual meeting. The winning presenter in the Posters Session receives a $3,500 prize and framed certificate. The winning presenter in the Fast Forward session receives $1,500 and a framed certificate. The Awards are presented at the Annual Scientific Meeting Dinner and details of the Award recipients are published on the AGITG website and in the Annual Report. 

1800 – 1930 Welcome Reception and Poster Walkaround

With focus on ‘walking in several groups around the posters’

Academics to accompany and discuss posters

  • Dr Deme Karikios
  • Dr Bryan Chan
  • Dr Belinda Lee

Thursday 27 August

0745 – 0845 Keynote Breakfast Session

Co-Chairs: TBC

Theme: TBA

Speaker: Professor Parry Guildford

0900 – 1100 Translational Science Symposium

Co-Chairs: Prof Phoebe Phillips & Prof Rob Ramsay

Theme: Concepts Changing Colorectal Cancer Control

This session will highlight the profound implications of the immune landscape in colorectal cancer articulated by the international leader in field who has demonstrated the role of tumour infiltrating lymphocytes in dictating the outcome of patients with CRC. In addition we will hear from Prof Desai who will report on a very recent advance in targeting one ofthe most intractable oncogenic drivers of many different forms of cancer that is mutant RAS.

  • Pioneer Immunologist transforming the understanding of colorectal cancer pathogenesis and therapy – Dr Jérôme Galon
  • Targeting the untractable and untargetable in patients with mCRC – Professor Jayesh Desai
1100 – 1130 Morning Tea
1130 – 1315 Translational Science Symposium 

Co-Chairs: Prof Oliver Sieber and Dr Susan Woods

Theme: Rectal Advances in GI Cancer

This session will be a showcase of the latest in GI cancer translational research in Australasia

Speakers:

  • Keynote Address – Professor Parry Guildford
  • Pancreatic cancer- Professor Phoebe Phillips
  • Early onset CRC – Associate Professor Dan Buchanan
  • Inflammation and Gastric Cancer – Dr Ashleigh Poh
1130 – 1315 Radiation Oncology & Surgical Workshop

Co-Chairs: TBC

Theme: TBC

Speakers:

  • Professor Corrie Marijnen
  • Associate Professor Sam Ngan
  • Professor Frank Frizelle
1130 – 1315 Joint Consumer / Study Coordinator Forum

Co-Chairs: Jan Mumford & Linda Chikazhe

  • Health Literacy of cancer patients – Dr Rachel Cameron
  • Registry, Platform Trials, Teletrials – Ms Anne Woollett
  • Recruitment and Retention – TBC
  • New Zealand – GI oncology trials (landscape/overview/treatment) – Dr Sarah Benge
1315 – 1415 Lunch 
1315 – 1415 Meet the experts from the Translational Science Symposium  
1415 – 1600 New Concepts Symposium  

Co-Chairs: TBC

The New Concepts Symposium is designed as a novel way to reach out to a wider spectrum of the group. This session provides an opportunity for delegates to present embryonic new concepts for feedback and discussion with the audience as well as comments from international guests in terms of perspective, international interest and relevance. A good idea can be tested and a perception gained on whether to take the concept forward to a more formal review by the Upper or Lower GI Working Party. The identification of other AGITG members who may wish to assist in progressing the concept as an AGITG supported protocol is also possible. The winner of the Best New Concept Award will receive a $3,500 prize and a framed certificate. The runner up will receive a $1,500 prize and framed certificate. The Awards are presented at the Annual Scientific Meeting Dinner and details of the Award recipients are published on the AGITG website and in the Annual Report

1600 – 1630 Afternoon Tea
1630 – 1800 Multidisciplinary Workshop

Chair: Associate Professor Sumitra Ananda

Theme: Oesophageal-Gastric Junction Cancer

The optimal multimodal approach to the management of locally advanced oesophagogastric junctional adenocarcinoma remains controversial. Both peri-operative chemotherapy and neoadjuvant chemoradiation improve survival over surgery alone. Using an illustrative case, international and local experts will discuss the pros and cons of either approach and the potential future role of biomarkers and molecular characteristics in determining treatment.

Invited Speakers, International

  • Dr Naureen Starling
  • Professor Kohei Shitara
  • Professor Corrie Marijnen
  • Dr Jérôme Galon

Invited Speakers, National

  • Professor Trevor Leong
  • Professor Parry Guildford
  • Mr Jeff Cuff
1900  – 1930 AGITG 22nd Annual Meeting Reception
1930  – 2200 AGITG 22nd Annual Meeting Dinner

Friday 28 August

0800 – 0915

 

 

 

 

Keynote Breakfast Session

Co-Chairs: TBC

Theme: Gastric Cancer

Speakers:

  • Professor Han-Kwang Yang
  • Professor Kohei Shitara – Update on Immunotherapy for Oesophagogastric cancers
0930 – 1055 AGITG Upper GI Cancer Research

Co-Chairs: Associate Professor Cuong Duong and TBC

ALT GIST: A Randomised Phase II trial of imatinib with regorafenib compared to inatnib alone for the first line treatment of advanced gastrointestinal stromal tumour (GIST)

DOCTOR: A RandomisedPhase II trial of pre-operative cisplatin, 5 fluorouracil and docetaxel +/- Radiotherapy, based on a poor early response to standardchemotherapy for rsectable adenocarcinoma of the oesophagus and/or gastro oesophageal junction – PRESENTED WITH DOCTOR Translational

CONTROL NETS: Capecitabine ON Temozolomide Radionuclide therapy Octreotate Lutetium-177 NeuroEndocrine Tumours Study

TOP GEAR: A Randomised Phase II/III trial of preoperative chemoradiotherapy vrsus preoperative chemotherapy for resectable gastric cancer

ALT-GIST, DOCTOR, CONTROL NETS & TOP GEAR: Where do they fit in the international context? – Professor Corrie Marijnen

DYNAMIC-Pancreas: Circulating Tumour DNA Analysis Informing Adjuvant Chemotherapy in Early Stage Pancreatic Cancer: A Multicentre Randomised Study

DYNAMIC Pancreas – Where does it fit in the International Context? – Dr Jérôme Galon

1055-1115 Morning Tea
1115-1305 AGITG Upper GI Cancer Research continues

ACTICCA-1: Adjuvant chemotherapy with gemcitabine and cisplatin cmplared to standard of care after curative intent resection of cholangiocarcinoma and muscle invasive gall bladder carcinoma

ACTICCA-1: Where does it fit in the International Context? – Dr Naureen Starling

NABNEC: A Randomised Phase II Study Of nab-paclitaxel In Combination With Carboplatin As First Line Treatment Of Gastrointestinal Neuroendocrine Carcinomas

NABNEC: Where does it fit in the International Context? – Professor Parry Guildford

MASTERPLAN: A Randomised Phase II Study of MFOLFIRINOX And Stereotactic Radiotherapy (SBRT) for Pancreatic Cancer with High Risk and Locally Advanced Disease

MASTERPLAN: Where does it fit in the International Context? – Professor Corrie Marijnen

INTEGRATE IIb: A Randomised Phase III Double-Blind Placebo-Controlled Study of regorafenib in Refactory Advanced Gastro-Oesophageal Cancer (AGOC)

INTEGRATE IIb: Where does it fit in the International Context? – Professor Kohei Shitara

AGITG ENDORSED STUDY

PALEO: PALiative oEsOphageal cancer chemoradioimmunotherapy: A multicentre Phase II Clinical Trial

PALEO: Where does it fit in the International Context? – Professor Corrie Marijnen

AGITG ENDORSED STUDY

Neo-CREATE: Neoadjuvant Immune-Chemo-Radiotherapy in operable oesophageal and gastro-oesophageal junction cancers with Carboplatin Paclitaxel Radiotherapy and Avelumab – a Trial assessing feasibility and preliminary Efficacy

Neo-CREATE: Where does it fit in the International Context? – Dr Naureen Starling

1305-1315 CLOSE OF ASM  
1345 Buses depart to the Airport